Signal active
Organization
Contact Information
Overview
Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.
Beta cell replacement is one of the most promising approaches for treatment of Insulin Dependent Diabetes Mellitus (IDDM). Currently, pancreas islet transplantation is the only approved cell replacement technology and it's the best available treatment for diabetics. However, it's impractical because of a shortage of donor tissue and rejection rate by the patient' immune system. Orgenesis believes that converting the diabetic patients own tissue to insulin producing cells will overcome the problem of donor shortage. Moreover, since the diabetic patient serves as his/her own donor, there is no risk of transplant rejection.
Orgenesis has manifested promising results in in-vitro and in-vivo studies using human liver tissues. Based on this significant discovery and these findings, Orgenesis has designed an efficient and clear work-plan to initiate clinical testing in the next few months allowing the company to launch phase I clinical trials following FDA guidelines followed by the launch of Phase II clinical trials within a year.
About
Biotechnology, Therapeutics, Health Diagnostics
2008
101-250
Headquarters locations
White Plains, New York, United States, North America
Social
Profile Resume
Orgenesis headquartered in New York, United States, North America, operates in the Biotechnology, Therapeutics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $7.5B in funding across 108 round(s). With a team of 101-250 employees, Orgenesis is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Orgenesis, raised $1.3M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
9
0
0
$69.3M
Details
0
Orgenesis has raised a total of $69.3M in funding over 0 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|
Investors
Orgenesis is funded by 8 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Orgenesis | - | FUNDING ROUND - Orgenesis | 1.6M |
Wallonia Regional Government | - | FUNDING ROUND - Wallonia Regional Government | 1.6M |
Orgenesis | - | FUNDING ROUND - Orgenesis | 16.0M |
Governing Dynamics Venture Capital | - | FUNDING ROUND - Governing Dynamics Venture Capital | 16.0M |
Recent Activity
News
Sep 23, 2024
Benzinga - Why Orgenesis (ORGS) Stock Is Down 23% Today
News
Sep 23, 2024
SeekingAlpha - Orgenesis announces 1-for-10 reverse stock split to regain Nasdaq compliance
News
Aug 14, 2024
thefly.com - Orgenesis announces JV partnership with Harley Street Healthcare Group
News
Jul 12, 2024
thefly.com - Orgenesis agrees to purchase assets from Broaden Bioscience
News
Jun 06, 2024
SeekingAlpha - Orgenesis files to sell 2.48M shares of common stock for holders
News
May 21, 2024
thefly.com - Orgenesis reports Q1 EPS (29c) vs (87c) last year